Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib in 2nd-line Advanced Pancreatic Cancer
NCT04415385Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in pancreatic cancer (PC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04415385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04415385.